Literature DB >> 21107532

Prevalence and costs of osteoporotic patients with subsequent non-vertebral fractures in the US.

C T Pike1, H G Birnbaum, M Schiller, E Swallow, R T Burge, E T Edgell.   

Abstract

UNLABELLED: This study assesses prevalence of subsequent fractures during the year after incident osteoporosis-related non-vertebral fractures among privately insured and Medicare populations and compares costs between patients with and without subsequent fractures. Many non-vertebral fracture patients incur subsequent fractures, and those who do are significantly more costly during the year after incident fracture.
INTRODUCTION: To estimate the prevalence of subsequent osteoporosis-related non-vertebral (NV) fractures during the year following an incident NV fracture and compare costs between NV fracture patients with and without subsequent fractures.
METHODS: Using insurance claims data (1999-2006), privately-insured (ages 18-64 years) and Medicare (ages 65+ years) patients with ≥1 subsequent osteoporosis-related NV fracture within a year of an incident osteoporosis-related NV fracture were matched to controls with incident NV fractures but no subsequent fractures. Subsequent fractures were identified as any claim for an NV fracture occurring >3 months after the incident NV fracture (>6 months were required for fractures occurring at the same site as the incident fracture). The study assessed prevalence of subsequent fractures and compared costs (from the payer's perspective) between patients with and without subsequent fractures over the year following an incident NV fracture.
RESULTS: Among privately insured NV fracture patients, 14.1% had any subsequent NV fractures, 1.6% had subsequent hip fractures, and 13.0% had subsequent non-vertebral, non-hip (NVNH) fractures, while 22.6% of Medicare NV fracture patients had subsequent NV fractures, 9.4% had subsequent hip fractures, and 15.5% had subsequent NVNH fractures. Mean excess health care costs per privately insured subsequent fracture patient were $9,789 ($19,072 vs. $9,914, p < 0.01), while excess medical costs per Medicare subsequent fracture patient were $12,527 ($31,904 vs. $19,377, p < 0.01).
CONCLUSIONS: NV fracture patients are at substantial risk for subsequent NV fractures within 1 year, and patients who incur subsequent fractures are significantly more costly than those who do not during the year following an incident fracture.

Entities:  

Mesh:

Year:  2010        PMID: 21107532     DOI: 10.1007/s00198-010-1494-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  33 in total

1.  Mortality after all major types of osteoporotic fracture in men and women: an observational study.

Authors:  J R Center; T V Nguyen; D Schneider; P N Sambrook; J A Eisman
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

2.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

3.  Fragility fracture-related direct medical costs in the first year following a nonvertebral fracture in a managed care setting.

Authors:  Robert L Ohsfeldt; Natalie N Borisov; Richard L Sheer
Journal:  Osteoporos Int       Date:  2005-09-29       Impact factor: 4.507

4.  The human cost of fracture.

Authors:  Julie A Pasco; Kerrie M Sanders; Frouckje M Hoekstra; Margaret J Henry; Geoffrey C Nicholson; Mark A Kotowicz
Journal:  Osteoporos Int       Date:  2005-10-14       Impact factor: 4.507

5.  Refractures in patients at least forty-five years old. a prospective analysis of twenty-two thousand and sixty patients.

Authors:  C M Robinson; M Royds; A Abraham; M M McQueen; C M Court-Brown; J Christie
Journal:  J Bone Joint Surg Am       Date:  2002-09       Impact factor: 5.284

6.  The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study.

Authors:  A Papaioannou; C C Kennedy; G Ioannidis; Y Gao; A M Sawka; D Goltzman; A Tenenhouse; L Pickard; W P Olszynski; K S Davison; S Kaiser; R G Josse; N Kreiger; D A Hanley; J C Prior; J P Brown; T Anastassiades; J D Adachi
Journal:  Osteoporos Int       Date:  2007-10-09       Impact factor: 4.507

7.  Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures.

Authors:  Lucinda Strycker Orsini; Matthew D Rousculp; Stacey R Long; Shaohung Wang
Journal:  Osteoporos Int       Date:  2004-09-01       Impact factor: 4.507

8.  Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study.

Authors:  Steven Boonen; Philippe Autier; Martine Barette; Dirk Vanderschueren; Paul Lips; Patrick Haentjens
Journal:  Osteoporos Int       Date:  2003-11-07       Impact factor: 4.507

9.  Orchidectomy models of osteoporosis.

Authors:  Stéphane Blouin; Hélène Libouban; Marie Françoise Moreau; Daniel Chappard
Journal:  Methods Mol Biol       Date:  2008

10.  10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program.

Authors:  Anthony B Hodsman; William D Leslie; James F Tsang; Greg D Gamble
Journal:  Arch Intern Med       Date:  2008-11-10
View more
  10 in total

1.  The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system.

Authors:  Daniel H Solomon; Amanda R Patrick; John Schousboe; Elena Losina
Journal:  J Bone Miner Res       Date:  2014-07       Impact factor: 6.741

2.  Obstructive Sleep Apnea and Risk for Incident Vertebral and Hip Fracture in Women.

Authors:  Tianyi Huang; Shelley S Tworoger; Susan Redline; Gary C Curhan; Julie M Paik
Journal:  J Bone Miner Res       Date:  2020-09-09       Impact factor: 6.741

Review 3.  Public health impact of osteoporosis.

Authors:  Jane A Cauley
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-07-31       Impact factor: 6.053

4.  Indirect costs account for half of the total costs of an osteoporotic fracture: a prospective evaluation.

Authors:  D A Eekman; M M ter Wee; V M H Coupé; S Erisek-Demirtas; M H Kramer; W F Lems
Journal:  Osteoporos Int       Date:  2013-09-27       Impact factor: 4.507

5.  Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis.

Authors:  Yang Sun; Yue Li; Jiangbi Li; Xiaoping Xie; Feng Gu; Zhenjiang Sui; Ke Zhang; Tiecheng Yu
Journal:  Front Pharmacol       Date:  2022-05-24       Impact factor: 5.988

6.  Self-reported sleep characteristics and risk for incident vertebral and hip fracture in women.

Authors:  Tianyi Huang; Susan Redline; Catherine M Gordon; Eva Schernhammer; Gary C Curhan; Julie M Paik
Journal:  Sleep Health       Date:  2022-02-28

7.  The association of coffee consumption with the risk of osteoporosis and fractures: a systematic review and meta-analysis.

Authors:  X Zeng; Y Su; A Tan; L Zou; W Zha; S Yi; Y Lv; T Kwok
Journal:  Osteoporos Int       Date:  2022-04-15       Impact factor: 5.071

8.  Awareness of osteoporosis and its relationship with calcaneus quantitative ultrasound in a large Chinese community population.

Authors:  Jingjing Xu; Min Sun; Zhixiao Wang; Qi Fu; Mengdei Cao; Zhenxin Zhu; Chuchen Meng; Yan Yan; Jia Mao; Hua Tao; Xiaoping Huang; Zheng Lin; Tao Yang; Wei He
Journal:  Clin Interv Aging       Date:  2013-06-27       Impact factor: 4.458

9.  Determinants of imminent fracture risk in postmenopausal women with osteoporosis.

Authors:  R L Barron; G Oster; A Grauer; D B Crittenden; D Weycker
Journal:  Osteoporos Int       Date:  2020-07-01       Impact factor: 4.507

10.  Treatment costs and cost drivers among osteoporotic fracture patients in Japan: a retrospective database analysis.

Authors:  Yurie Taguchi; Yuta Inoue; Taichi Kido; Nobuhiro Arai
Journal:  Arch Osteoporos       Date:  2018-04-25       Impact factor: 2.617

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.